Jung Min Lee

Jung Min Lee

Auto-generated profile, based on publicly available information

Jung Min Lee

Department of Surgery, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in HPB
Verified
Journal Article
Closed access
JLJung M. Lee
Jung M. Lee
JKJae S. Kang
Jae S. Kang
YCYoo J. Choi
Yoo J. Choi
YBYoonhyeong Byun
Yoonhyeong Byun
SJShi H. Jin
Shi H. Jin
CLChang-Sup Lim
Chang-Sup Lim

1 July 2008 in Antiviral Therapy
Verified
Journal Article
Open access
JLJung Min Lee
Jung Min Lee
HKHyung Joon Kim
Hyung Joon Kim
JPJun Yong Park
Jun Yong Park
CLChun Kyon Lee
Chun Kyon Lee
Do Young KimDo Young Kim
Do Young Kim
SASang Hoon Ahn
Sang Hoon Ahn
Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)- positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg serocon-version, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351), HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%), IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.

1 October 2005 in Macromolecular Research
Verified
Journal Article
Closed access
PDF file
JLJung Min Lee
Jung Min Lee
SSSankaraiah Subramani
Sankaraiah Subramani
YLYoung Soo Lee
Young Soo Lee
Jung Hyun KimJung Hyun Kim
Jung Hyun Kim

31 August 2021 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
MOMoon Young Oh
Moon Young Oh
HKHongbeom Kim
Hongbeom Kim
YCYoo Jin Choi
Yoo Jin Choi
YBYoonhyeong Byun
Yoonhyeong Byun
YHYoungmin Han
Youngmin Han
JJJin-Young Jang
Jin-Young Jang
Moon Young Oh, Hongbeom Kim, Yoo Jin Choi, Yoonhyeong Byun, Youngmin Han, Jae Seung Kang, Heeju Sohn, Jung Min Lee, Wooil Kwon, Jin-Young Jang. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. https://doi.org/10.14701/ahbps.2021.25.3.349

1 January 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JLJung Min Lee
Jung Min Lee
HKHongbeom Kim
Hongbeom Kim
HSHee Ju Sohn
Hee Ju Sohn
YCYoo Jin Choi
Yoo Jin Choi
JKJae Seung Kang
Jae Seung Kang
JJJin-Young Jang
Jin-Young Jang
Lee JM, et al. Ann Surg Treat Res. 2022 Feb;102(2):100-109. https://doi.org/10.4174/astr.2022.102.2.100

1 January 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
HSHee Ju Sohn
Hee Ju Sohn
HKHongbeom Kim
Hongbeom Kim
SKSun Joo Kim
Sun Joo Kim
KLKyoung Bun Lee
Kyoung Bun Lee
YHYoungmin Han
Youngmin Han
JJJin-Young Jang
Jin-Young Jang
Sohn HJ, et al. Ann Surg Treat Res. 2022 Jan;102(1):10-19. https://doi.org/10.4174/astr.2022.102.1.10